Static Chart CervoMed Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
19.01 ^USD	-3.80%		-0.94%	+149.15%

Jun. 11	CervoMed Inc. Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies	CI
May. 29	JonesTrading Starts CervoMed With Buy Rating, $70 Price Target	MT

Duration

Period